¾Ï ´ÜŬ·ÐÇ×ü ½ÃÀå º¸°í¼­ : Ç×ü À¯Çüº°, ¾à¹° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°(2025-2033³â)
Cancer Monoclonal Antibodies Market Report by Antibody Type, Medication Type (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, and Others), Application, End-User, and Region 2025-2033
»óǰÄÚµå : 1660680
¸®¼­Ä¡»ç : IMARC Group
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 144 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,339,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,786,000
PDF & Excel (5 User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 7,233,000
PDF & Excel (Corporate License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

IMARC GroupÀº 2024³â ¼¼°è ¾Ï ´ÜŬ·ÐÇ×ü ½ÃÀå ±Ô¸ð°¡ 483¾ï ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç, 2025³âºÎÅÍ 2033³â±îÁö 3.4%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 2033³â¿¡´Â 655¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

¾Ï ´ÜŬ·ÐÇ×ü¶õ ¾Ï¼¼Æ÷¿¡ ´ëÇÑ ¸é¿ªÃ¼°èÀÇ °ø°ÝÀ» ¸ð¹æÇϵµ·Ï ¼³°èµÈ ½ÇÇè½Ç¿¡¼­ »ý¼ºµÈ ºÐÀÚ¸¦ ¸»ÇÕ´Ï´Ù. ¾Ï¼¼Æ÷ Ç¥¸é¿¡ Á¸ÀçÇÏ´Â Ç׿ø°ú °áÇÕÇÏ¿© ¼¼Æ÷¸· ÆÄ±« ¹× ¼¼Æ÷ Áõ½Ä ¾ïÁ¦, ¸é¿ªÃ¼°è ¾ïÁ¦¸¦ À¯¹ßÇÏ´Â Ç÷¡±×¸¦ ¼¼¿ï ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ä¡·á¿ë ¹æ»ç¼±À» ¾Ï¼¼Æ÷¿¡ Á÷Á¢ Á¶»çÇÏ¿© ¾Ï¼¼Æ÷¸¦ ÁßÈ­ ¶Ç´Â ÆÄ±«ÇÒ ¼öµµ ÀÖ½À´Ï´Ù. °¡Àå ÀϹÝÀûÀ¸·Î »ç¿ëµÇ´Â ´ÜŬ·ÐÇ×ü¿¡´Â ¸¶¿ì½º Ç×ü, Ű¸Þ¶ó Ç×ü, Àΰ£È­ Ç×ü µîÀÌ ÀÖÀ¸¸ç, Ç÷¾×, °£, ³ú, À¯¹æ¾Ï µîÀÇ ¾Ï Ä¡·á¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

Àü ¼¼°èÀûÀ¸·Î ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. È­Çпä¹ý µî ±âÁ¸¿¡ »ç¿ëµÇ´ø ºñÇ¥Àû Ä¡·á¹ý¿¡ ºñÇØ ´ÜŬ·ÐÇ×ü´Â ȯÀÚÀÇ ½Åü¿¡ ¹ÌÄ¡´Â ºÎÀÛ¿ëÀÌ Àû°í, ÀÚ°¡¸é¿ªÁúȯ ¹× ¿°Áõ¼º ÁúȯÀÇ Ä¡·á¿¡µµ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºñ¿ë È¿À²¼ºÀÌ ³ôÀº ¹ÙÀÌ¿À½Ã¹Ð·¯ ´ÜŬ·ÐÇ×ü°¡ °³¾÷ÀÇ¿Í Á¾¾ç Àü¹®ÀÇ¿¡°Ô ³Î¸® äÅõǰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ½ÃÄö½Ì ¹× Ç¥Àû À¯ÀüÀÚ ¼±Åà ±â¼úÀÌ ¹ßÀüÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ Ç×ü´Â ÀǾàǰ°ú À¯»çÇÑ Æ¯¼ºÀ» °®µµ·Ï º¯ÇüµÉ ¼ö ÀÖ½À´Ï´Ù. µ¿ÀÏÇÑ È¿À²À» °¡Áö¸é¼­µµ ¿À¸®Áö³Î ÀǾàǰº¸´Ù Àú·ÅÇÏ°Ô ±¸ÀÔÇÒ ¼ö ÀÖ¾î Ä¡·áÀÇ ºñ¿ë È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, ÇコÄɾî ÀÎÇÁ¶óÀÇ ´ëÆøÀûÀÎ °³¼± µî ´Ù¸¥ ¿äÀε鵵 ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

Á¦5Àå ¼¼°èÀÇ ¾Ï ´ÜŬ·ÐÇ×ü ½ÃÀå

Á¦6Àå ½ÃÀå ³»¿ª : Ç×ü À¯Çüº°

Á¦7Àå ½ÃÀå ³»¿ª : ¾à¹° À¯Çüº°

Á¦8Àå ½ÃÀå ³»¿ª : ¿ëµµº°

Á¦9Àå ½ÃÀå ³»¿ª : ÃÖÁ¾ ¿ëµµº°

Á¦10Àå ½ÃÀå ³»¿ª : Áö¿ªº°

Á¦11Àå SWOT ºÐ¼®

Á¦12Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global cancer monoclonal antibodies market size reached USD 48.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 65.5 Billion by 2033, exhibiting a growth rate (CAGR) of 3.4% during 2025-2033.

A cancer monoclonal antibody refers to a laboratory-generated molecule that is engineered to mimic the immune system's attack on cancer cells. It can bind to antigens present on the surface of cancer cells and flag them to trigger the destruction of cell membranes, block cell growth and immune system inhibitors. It can also deliver treatment radiations directly to the cancer cells to neutralize or destroy them. Some of the most commonly used monoclonal antibodies include murine, chimeric and humanized antibodies that are employed in the treatment of cancer in the blood, liver, brain and breast.

The increasing prevalence of cancer across the globe is one of the key factors driving the growth of the market. In comparison to traditionally used non-targeted therapies, such as chemotherapy, monoclonal antibodies have reduced side-effects on the patient's body and can also be used for the treatment of autoimmune and inflammatory diseases. Furthermore, widespread adoption of cost-efficient biosimilar monoclonal antibodies by medical practitioners and oncologists is also providing a boost to the market growth. With technological advancements in gene sequencing and target gene selection, these antibodies can be modified to have similar properties to that of a pharmaceutical drug. They have the same efficiency but are available at reduced prices than the original medicine, which aids in enhancing the cost-efficiency of the treatment, thereby contributing to the increasing demand for the product across the globe. Other factors, including rising preference for personalized medicines, extensive research and development (R&D) activities and significant improvements in the healthcare infrastructure, are projected to drive the market further.

Key Market Segmentation:

Breakup by Antibody Type:

Breakup by Medication Type:

Breakup by Application:

Breakup by End-User:

Breakup by Region:

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genmab A/S, GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Seattle Genetics Inc., Spectrum Pharmaceuticals Inc., etc.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cancer Monoclonal Antibodies Market

6 Market Breakup by Antibody Type

7 Market Breakup by Medication Type

8 Market Breakup by Application

9 Market Breakup by End-User

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â